Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 3, 2008, Pages 205-208

  Rech, Jürgen ^a   Hueber, Axel J ^a   Kallert, Stefan ^a   Leipe, Jan ^b   Kalden, Jochen R ^a   Beck, Marcus ^c   Schett, Georg ^a   Schulze Koops, Hendrik ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Anti CD20 antibody; Anti myelin associated glycoprotein antibody; Demyelinating polyneuropathy; Extracorporeal therapy; Immunoadsorption

Indexed keywords

ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; RITUXIMAB;

ACTION POTENTIAL; AGED; ARTICLE; CASE REPORT; DEMYELINATING POLYNEUROPATHY; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE REDUCTION; HOSPITAL ADMISSION; HUMAN; IMMUNOADSORPTION; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; LOW DRUG DOSE; MALE; NERVE CONDUCTION; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; REMISSION; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; DEMYELINATING DISEASES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; MALE; MYELIN-ASSOCIATED GLYCOPROTEIN; POLYNEUROPATHIES; TREATMENT OUTCOME;

EID: 44349190819     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00573.x     Document Type: Article

References (14)

1. Steck AJ, Erne B, Gabriel JM, Schaeren-Wiemers N. Paraproteinaemic neuropathies. Brain Pathol 1999 9 : 361 8.
2. Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM -proteins and its relationship to immune therapies. Brain 2000 123 : 710 17.
3. Pestronk A, Li F, Griffin J et al. Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991 41 : 357 62.
4. Erb S, Ferracin F, Fuhr P et al. Polyneuropathy attributes: a comparison between patients with anti-MAG and anti-sulfatide antibodies. J Neurol 2000 247 : 767 72.
5. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994 117 : 941 7.
6. Oksenhendler E, Chevret S, Leger J-M, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 1995 59 : 243 7.
7. Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995 45 : 1577 80.
8. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999 52 : 1701 4.
9. Renaud S, Fuhr P, Gregor M et al. High-dose rituximab and anti-MAG associated polyneuropathy. Neurology 2006 66 : 742 4.
10. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr. Opin. Phamacol. 2004 4 : 398 402.
11. Smith IS. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. Brain 1994 11 : 949 57.
12. Euler HH, Schroeder JO, Loffler H. Antibody depletion and cytotoxic drug therapy in systemic lupus erythematosus. Transfus Sci 1992 13 : 167 84.
13. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003 74 : 485 9.
14. Renaud S, Gregor M, Fuhr P et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003 27 : 611 15.